Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Virology"
DOI: 10.1002/jmv.26279
Abstract: The role of disease‐modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease‐2019 (COVID‐19) due to the absence… read more here.
Keywords: cov2 infection; sars cov2; fingolimod withdrawal; fingolimod ... See more keywords
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09195-2
Abstract: BackgroundIt has been described that treating relapsing–remitting multiple sclerosis (RRMS) patients with alemtuzumab following fingolimod could be less effective due to the different dynamics of lymphocyte repopulation. Effectiveness and safety of alemtuzumab compared to rituximab… read more here.
Keywords: rituximab fingolimod; alemtuzumab rituximab; fingolimod withdrawal; fingolimod ... See more keywords